CLTA and Alzheimer disease: Table 1 lists proteins involved in CME whose mRNA are predicted targets of AD CSF miRNAs. Of these, we evaluated ITSN1, CLTA, and PICALM for changes in expression between male and female CTL and AD brain. We also quantified FCHO1, AP2A1, and DNM2 as these are integral to CME and implicated as disrupted in AD (Nakamura et al., 1994; Yao et al., 2000; Wilmot et al., 2008; Malakooti, 2019; Du et al., 2021; Teerlink et al., 2021; Srinivasan et al., 2022), but are not predicted targets of the AD CSF miRNAs.